Abstract:Innovative and easy-to-implement strategies are needed to improve the pathogenicity assessment of rare germline missense variants. Somatic cancer driver mutations identified through large-scale tumor sequencing studies often impact genes that are also associated with rare Mendelian disorders. The use of cancer mutation data to aid in the interpretation of germline missense variants, regardless of whether the gene is associated with a hereditary cancer predisposition syndrome or a non-cancer-related developmental disorder, has not been systematically assessed. We extracted putative cancer driver missense mutations from the Cancer Hotspots database and annotated them as germline variants, including presence/absence and classification in ClinVar. We trained two supervised learning models (logistic regression and random forest) to predict variant classifications of germline missense variants in ClinVar using Cancer Hotspot data (training dataset). The performance of each model was evaluated with an independent test dataset generated in part from searching public and private genome-wide sequencing datasets from ~1.5 million individuals. Of the 2,447 cancer mutations, 691 corresponding germline variants had been previously classified in ClinVar: 426 (61.6%) as likely pathogenic/pathogenic, 261 (37.8%) as uncertain significance, and 4 (0.6%) as likely benign/benign. The odds ratio for a likely pathogenic/pathogenic classification in ClinVar was 28.3 (95% confidence interval: 24.2-33.1, p < 0.001), compared with all other germline missense variants in the same 216 genes. Both supervised learning models showed high correlation with pathogenicity assessments in the training dataset. There was high area under precision-recall curve values of 0.847 and 0.829 for logistic regression and random forest models, respectively, when applied to the test dataset. With the use of cancer and germline datasets and supervised learning techniques, our study shows that cancer mutation data can be leveraged to improve the interpretation of germline missense variation potentially causing rare Mendelian disorders.

Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects

Assessment of Computational Methods for Predicting the Effects of Missense Mutations in Human Cancers.

Leveraging cancer mutation data to predict the pathogenicity of germline missense variants

CanPredict: a Computational Tool for Predicting Cancer-Associated Missense Mutations

Analytical Methods for Inferring Functional Effects of Single Base Pair Substitutions in Human Cancers

Predicting non-neutral missense mutations and their biochemical consequences using genome-scale homology modeling of human protein complexes

Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2

A Computational Workflow for Analysis of Missense Mutations in Precision Oncology

Understanding the impacts of missense mutations on structures and functions of human cancer-related genes: A preliminary computational analysis of the COSMIC Cancer Gene Census

Comparison of Predicted and Actual Consequences of Missense Mutations.

Identification of Key Somatic Oncogenic Mutation Based on a Confounder-Free Causal Inference Model

Distinguishing Driver Missense Mutations from Benign Polymorphisms in Breast Cancer.

Predicting Pathology of Missense Mutations through Protein-Specific Evolutionary Pattern

DVA: Predicting the Functional Impact of Single Nucleotide Missense Variants

Genome-wide Mutational Spectra Analysis Reveals Significant Cancer-Specific Heterogeneity

Inferring the Functional Effects of Mutation Through Clusters of Mutations in Homologous Proteins.

Detecting and understanding meaningful cancerous mutations based on computational models of mRNA splicing

Computational Prediction Of Driver Missense Mutations In Melanoma

e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks

Incorporating mutational heterogeneity to identify genes that are enriched for synonymous mutations in cancer